2025-03-13

pocket turtle, Musk's drugs, ancient cancellations, terrorist academe, telecom insecurity, alien flick, Apple sued for minerals, DptEd layoffs, charging fraud, ozempocalypse nigh, bird flu and lab leaks


Horseshit


Musk

Religion / Tribal / Culture War and Re-Segregation

  • Orson Scott Card: Casualty of Culture Wars

    Here’s the quandary: what does the “secular humanism” Card spoke of do with the people it leaves behind? Card’s view at the time left no room for the sort of reconciliation that is my instinct, the polite but strongly felt disagreement between two people aligned on more fundamental matters. I want to be on the side of the Orson Scott Card pushing for secularism and cooperation in the ‘90s, against evangelicals pushing young-earth creationism in schools and censorious progressives alike, while at the same time feeling a sense of impossibility at understanding how to cooperate with the Card who spoke of gay marriage as a threat to the Republic so profound it would merit tearing the government to the ground. Even with that impossibility, though, I retain the sense that Card was wronged, as are many good people who see the times move on from them. People fixate so much, so exclusively, on the area of dissonance between his frame and theirs that everything else fades into irrelevance, that one of the most earnest and humanizing authors of our day becomes known in pop culture only as the one who was against gay marriage. It’s not that it’s unfair to judge people on the fights they pick, precisely—but I cannot help but see it as profoundly tragic to reduce them to that and become incapable of seeing or talking about anything but that dissonance.

Edumacationalizing / Acedemia Nuts

  • Yale Scholar Banned After A.I. News Site Accuses Her of Terrorist Link - The New York Times

    Helyeh Doutaghi, a scholar in international law, began a new job in 2023 as the deputy director of a project at Yale Law School. As an activist who had championed pro-Palestinian causes in both published papers and public appearances, Dr. Doutaghi seemed to fit into the left-leaning mission of the Law and Political Economy Project, which promoted itself as working for “economic, racial and gender equality.” Last week, though, she was abruptly barred from Yale’s campus in New Haven, Conn., and placed on administrative leave. She was told not to advertise her affiliation with the university, where she had also served as an associate research scholar. Yale officials cited the reason as allegations that she was tied to entities subject to U.S. sanctions. It was an apparent reference to Samidoun, a pro-Palestinian group placed on the U.S. sanctions list last year, after the Treasury Department designated it a “sham charity” raising money for a terrorist organization, the Popular Front for the Liberation of Palestine. The decision came three days after a news site, powered at least in part by artificial intelligence, published a story about Dr. Doutaghi’s connections to the group. The swift action against Dr. Doutaghi illustrates the tightrope American universities are walking as the Trump administration takes aim at higher education.

Info Rental / ShowBiz / Advertising

TechSuck / Geek Bait

Space / Boomy Zoomers / UFO

Economicon / Business / Finance

Left Angst

External Security / Militaria / Diplomania

Health / Medicine

  • The Ozempocalypse Is Nigh

    So for the past three years, telehealth startups working with compounding pharmacies have sold these drugs for about $200/month. Over two million Americans have made use of this loophole to get weight loss drugs for cheap. But there was always a looming question - what happens when the shortage ends? Many people have to stay on GLP-1 drugs permanently, or else they risk regaining their lost weight. But many can’t afford $1000/month. What happens to them? Now we’ll find out. At the end of last year, the FDA declared the shortage over. The compounding pharmacies appealed the decision, but last month the FDA confirmed its decision was final. As of March 19 (for tirzepatide) and April 22 (for semaglutide), compounding pharmacies will no longer be able to sell cheap GLP-1 drugs. Let’s take a second to think of the real victims here: telehealth company stockholders.

    overall, I think the past two years have been a fun experiment in semi-free-market medicine. It’s no surprise that you can sell drugs cheap if you violate the patent. But it is interesting that the non-cost aspects work out so well. For the past three years, ~2 million people have taken complex peptides provided direct-to-consumer by a less-regulated supply chain, with barely a fig leaf of medical oversight, and it went great. There were no more side effects than any other medication. People who wanted to lose weight lost weight. And patients had a more convenient time than if they’d had to wait for the official supply chain to meet demand, get a real doctor, spend thousands of dollars on doctors’ visits, apply for insurance coverage, and go to a pharmacy every few weeks to pick up their next prescription. Now pharma companies have noticed and are working on patent-compliant versions of the same idea.

  • Contrary to Popular Belief, CPR Is Not as Successful as Many Think

  • Children under eight should avoid slushies as glycerol leads to hospitalisations

  • Why Some Men Find Orgasms Elusive

Pox / COVID / BioTerror AgitProp